SCHEMBL1668232

SCHEMBL1668232

CS(=O)(=O)N1CCN(c2ncc(OC3CN(Cc4ccc(C(F)(F)F)cc4)C3)cn2)CC1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.53
ALDH1A1 P00352 1/20 0.53
NPC1 O15118 1/20 0.44
RAB9A P51151 1/20 0.44
CASP1 P29466 1/20 0.40
CASP4 P49662 1/20 0.40
CASP5 P51878 1/20 0.40
PRKAA2 P54646 1/20 0.40
IDO1 P14902 1/20 0.40
CHRM2 P08172 3/20 0.40
CHRM1 P11229 3/20 0.40
CHRM4 P08173 1/20 0.40
LMNA P02545 1/20 0.39
CYP3A4 P08684 1/20 0.39
ADRB2 P07550 1/20 0.39
PPARD Q03181 2/20 0.39
PPARA Q07869 2/20 0.39
CHRM3 P20309 2/20 0.38
HIF1A Q16665 1/20 0.38
EPAS1 Q99814 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15368986 0.89 KDM4E (0.46) KDM4EALDH1A1NPC1RAB9AIDO1
SCHEMBL1670031 0.89 KDM4E (0.51) KDM4EALDH1A1PRKAA2CHRM2CHRM1
SCHEMBL12198381 0.85 KDM4E (0.51) KDM4EALDH1A1CASP1CASP4CASP5
SCHEMBL1668538 0.83 KDM4E (0.51) KDM4EALDH1A1CASP1CASP4CASP5
SCHEMBL12198260 0.80 KDM4E (0.48) KDM4EALDH1A1CASP1CASP4CASP5
SCHEMBL1668348 0.79 KDM4E (0.45) KDM4EALDH1A1PRKAA2CHRM2CHRM1
SCHEMBL12198261 0.79 KDM4E (0.47) KDM4EALDH1A1PRKAA2CYP3A4ADRB2
SCHEMBL2508495 0.79 CHRM2 (0.44) KDM4EALDH1A1PRKAA2CHRM2CHRM1
SCHEMBL1668235 0.79 KDM4E (0.53) KDM4EALDH1A1PPARDPPARACYP2D6
SCHEMBL2511657 0.78 S1PR1 (0.42) KDM4EALDH1A1PRKAA2LMNAPPARG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8575168-B2 Compounds and compositions as modulators of GPR119 activity IRM LLC (BM) 2013-11-05 US claimed
EP-2486033-A1 COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY IRM LLC (BM) 2012-08-15 EP claimed
US-20110245220-A1 COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY IRM LLC (BM) 2011-10-06 US claimed
WO-2011044001-A1 COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY IRM LLC (BM) 2011-04-14 WO claimed
US-8575168-B2 Compounds and compositions as modulators of GPR119 activity IRM LLC (BM) 2013-11-05 US disclosed
EP-2486033-A1 COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY IRM LLC (BM) 2012-08-15 EP disclosed
US-20110245220-A1 COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY IRM LLC (BM) 2011-10-06 US disclosed
WO-2011044001-A1 COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY IRM LLC (BM) 2011-04-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110245220-A1 COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY GPR119, GPR65, GPR39 KDM4E 3454/4885ALDH1A1 2341/4885NPC1 298/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.